GlobalRPh RX List - GAVRETO
- Product / population
- Pralsetinib - GAVRETO capsules; selected renal passages, not a complete prescribing monograph.
- Renal measure
- Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Boundary ambiguity preserved: retrieved source prints <15, not <30.
Renal dosing, restrictions and evidence limits
The RX PK passage reports no exposure effect at CrCl 30-89 mL/min. It then calls CrCl <15 severe impairment and states that group was not studied. Its wording leaves the 15-29 interval unaddressed; it is not silently rewritten as <30 or filled with a guessed dose. Renal dysfunction and dehydration are also listed among tumor-lysis risk factors. Retain monitoring and obtain an exact controlling-label review for the unaddressed range. This selected PK statement is not a complete renal prescribing algorithm.